Leukocyte telomere length in HIV-infected and HIV-exposed uninfected children: shorter telomeres with uncontrolled HIV viremia

PLoS One. 2012;7(7):e39266. doi: 10.1371/journal.pone.0039266. Epub 2012 Jul 16.

Abstract

Objectives: Nucleoside reverse transcriptase inhibitors (NRTIs) used in HIV antiretroviral therapy can inhibit human telomerase reverse transcriptase. We therefore investigated whether in utero or childhood exposure to NRTIs affects leukocyte telomere length (LTL), a marker of cellular aging.

Methods: In this cross-sectional CARMA cohort study, we investigated factors associated with LTL in HIV-1-infected (HIV(+)) children (n = 94), HIV-1-exposed uninfected (HEU) children who were exposed to antiretroviral therapy (ART) perinatally (n = 177), and HIV-unexposed uninfected (HIV(-)) control children (n = 104) aged 0-19 years. Univariate followed by multivariate linear regression models were used to examine relationships of explanatory variables with LTL for: a) all subjects, b) HIV(+)/HEU children only, and c) HIV(+) children only.

Results: After adjusting for age and gender, there was no difference in LTL between the 3 groups, when considering children of all ages together. In multivariate models, older age and male gender were associated with shorter LTL. For the HIV(+) group alone, having a detectable HIV viral load was also strongly associated with shorter LTL (p = 0.007).

Conclusions: In this large study, group rates of LTL attrition were similar for HIV(+), HEU and HIV(-) children. No associations between children's LTL and their perinatal ART exposure or HIV status were seen in linear regression models. However, the association between having a detectable HIV viral load and shorter LTL suggests that uncontrolled HIV viremia rather than duration of ART exposure may be associated with acceleration of blood telomere attrition.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anti-HIV Agents / pharmacology
  • Child
  • Child, Preschool
  • Environmental Exposure / adverse effects*
  • Female
  • HIV Infections / blood
  • HIV Infections / genetics
  • HIV Infections / pathology*
  • HIV Infections / prevention & control
  • Humans
  • Infant
  • Leukocytes / drug effects*
  • Leukocytes / pathology*
  • Linear Models
  • Male
  • Pregnancy
  • Reverse Transcriptase Inhibitors / pharmacology
  • Telomerase / antagonists & inhibitors
  • Telomere / drug effects*
  • Telomere / genetics
  • Telomere / pathology*
  • Viremia / blood
  • Viremia / genetics
  • Viremia / pathology*
  • Viremia / prevention & control
  • Young Adult

Substances

  • Anti-HIV Agents
  • Reverse Transcriptase Inhibitors
  • Telomerase